ArticleEuropean journal of nuclear medicine and molecular imaging2022
A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Sub-0.5-mm Resolution PET Versus Autoradiography: Comparison of mGluR1 Concentrations in Mouse Brain.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- PET imaging of alpha-synuclein: from radiotracer design through in vitro and in vivo translation.European journal of nuclear medicine and molecular imaging · 2026Review
- Repetitive mild traumatic brain injury with the closed-head impact model of engineered rotational acceleration (CHIMERA) promotes tau pathology in tau transgenic mice and its propagation in brains injected with tau fibrils.Acta neuropathologica communications · 2026Article
- Relationship Between Reactive Astrocytes, by [Molecular neurobiology · 2024Article
- Diagnostic and therapeutic targeting of pathological tau proteins in neurodegenerative disorders.FEBS open bio · 2024Review
- Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers.FEBS open bio · 2024Review
- A novel tauopathy model mimicking molecular and spatial aspects of human tau pathology.Brain communications · 2024Article
- Aggregation, Transmission, and Toxicity of the Microtubule-Associated Protein Tau: A Complex Comprehension.International journal of molecular sciences · 2023Review
- Submillimeter-Resolution PET for High-Sensitivity Mouse Brain Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Limitations of human tau-expressing mouse models and novel approaches of mouse modeling for tauopathy.Frontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDepositions of tau fibrils are implicated in diverse neurodegenerative disorders, including Alzheimer's disease, and precise assessments of tau pathologies and their impacts on neuronal survival are crucial for pursuing the neurodegenerative tau pathogenesis with and without potential therapies. We aimed to establish an in vivo imaging system to quantify tau accumulations with positron emission tomography (PET) and brain atrophy with volumetric MRI in rTg4510 transgenic mice modeling neurodegenerative tauopathies.
methodsA total of 91 rTg4510 and non-transgenic control mice underwent PET with a tau radiotracer,
results
conclusionOur imaging platform has enabled the quantification of tau depositions and consequent neuronal loss and is potentially applicable to the evaluation of candidate anti-tau and neuroprotective drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.